These days cancer has become a common cause of concern for many. Various researchers around the globe are trying to find out solutions to provide comfort to cancer patients in the best possible way.
Similarly North Korea, some patients are going through the first clinical trial of the anti-cancer treatment named 'CAR-T' (chimeric anticancer drug) after it has been developed.
It was on October 20, that the Korean Advanced Institute of Science and Technology announced that a research team led by professor KimChan-hyuk from the department of Biosciences has transferred CAR-T Cell-based therapy technology to Curocell, co-founded by Professor Kim.
CAR-T cell therapy is a kind of drug of immune anticancer drug that genetically transformed the attack cancer cells by introducing CAR genes to T-cells which are immune cells.The clinical trial phase1-b is being conducted on 10patients with Diffused Large B-cell Lymphoma. It is the stage it was further informed that the safety and effectiveness of the treatment are being evaluated in this stage.
Following this, the 2nd phase of the clinical trials will be conducted on 70 patients by the next year.
CAR-T cell therapy is a kind of drug of immune anticancer drug that genetically transformed the attack cancer cells by introducing CAR genes to T-cells which are immune cells.
This therapy is also called a "miracle anticancer drug' as it shows a high therapeutic effect of more than 80% in clinical trials on patients with end-stage leukaemia. CAR-T cell therapy is a novel tumour immunotherapy technique for cancer treatment.